Double-Targeting CAR-T cells aim to outsmart lymphoma relapse

NCT ID NCT07461831

Ongoing Disease control Sponsor: Beijing Tongren Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests a new type of CAR-T cell therapy that targets two proteins (CD19 and CD22) on lymphoma cells, aiming to prevent the cancer from escaping treatment. It involves 100 adults with relapsed or refractory large B-cell lymphoma who have not responded to standard therapies. The main goal is to see how many patients achieve a significant reduction in tumor size within three months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CD19/CD22 bispecific CAR-T cells
What this could lead to: If successful, this therapy could offer a more effective treatment option for patients with hard-to-treat large B-cell lymphoma, potentially reducing the chance of relapse.
What could go wrong: This is a single-center, phase 2 trial with 100 participants, so results may not apply broadly. CAR-T therapy carries risks like severe immune reactions and side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LARGE B-CELL LYMPHOMA (LBCL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

large B-cell lymphoma relapsed/refractory diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LARGE B-CELL LYMPHOMA (LBCL)

Contacts and locations

Locations

Beijing Tongren Hospital, Capital Medical University

Beijing, Beijing Municipality, 100730, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.